140 related articles for article (PubMed ID: 30905456)
1. Serum CA153 as biomarker for cancer and noncancer diseases.
Li X; Xu Y; Zhang L
Prog Mol Biol Transl Sci; 2019; 162():265-276. PubMed ID: 30905456
[TBL] [Abstract][Full Text] [Related]
2. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases.
He Y; Lu H; Zhang L
Prog Mol Biol Transl Sci; 2019; 162():199-212. PubMed ID: 30905450
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past 6 years.
Zhang M; Dou H; Yang D; Shan M; Li X; Hao C; Zhang Y; Zeng P; He Y; Liu Y; Fu J; Wang W; Hu M; Li H; Tian Q; Lei S; Zhang L
Prog Mol Biol Transl Sci; 2019; 162():141-163. PubMed ID: 30905446
[TBL] [Abstract][Full Text] [Related]
4. Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera.
Choi JW; Moon BI; Lee JW; Kim HJ; Jin Y; Kim HJ
Oncol Rep; 2018 Jul; 40(1):145-154. PubMed ID: 29749490
[TBL] [Abstract][Full Text] [Related]
5. CA242 as a biomarker for pancreatic cancer and other diseases.
Dou H; Sun G; Zhang L
Prog Mol Biol Transl Sci; 2019; 162():229-239. PubMed ID: 30905452
[TBL] [Abstract][Full Text] [Related]
6. Serum CEA levels in 49 different types of cancer and noncancer diseases.
Hao C; Zhang G; Zhang L
Prog Mol Biol Transl Sci; 2019; 162():213-227. PubMed ID: 30905451
[TBL] [Abstract][Full Text] [Related]
7. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer.
Tang Y; Cui X; Xiao H; Qi S; Hu X; Yu Q; Shi G; Zhang X; Gu J; Yu Y; Wang L; Li Y
Mol Med Rep; 2017 May; 15(5):2659-2664. PubMed ID: 28447743
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and prognostic significance of preoperative serum CA153, CEA and TPS levels in patients with primary breast cancer].
Chen Y; Zheng YH; Lin YY; Hu MH; Chen YS
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):842-6. PubMed ID: 22335950
[TBL] [Abstract][Full Text] [Related]
9. Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis.
Jiang X; Guo D; Li W; Yu T; Zhou J; Gong J
Mol Med Rep; 2017 Mar; 15(3):1123-1134. PubMed ID: 28112378
[TBL] [Abstract][Full Text] [Related]
10. Serum SCCA levels in patients suffering cancers or other diseases.
Yang D; Wang J; Zhang L
Prog Mol Biol Transl Sci; 2019; 162():165-175. PubMed ID: 30905447
[TBL] [Abstract][Full Text] [Related]
11. Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers.
Zhang M; Zhang Y; Fu J; Zhang L
Prog Mol Biol Transl Sci; 2019; 162():241-252. PubMed ID: 30905453
[TBL] [Abstract][Full Text] [Related]
12. Serum CA50 levels in patients with cancers and other diseases.
Shan M; Tian Q; Zhang L
Prog Mol Biol Transl Sci; 2019; 162():187-198. PubMed ID: 30905449
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactivity between MUC1 antigen and MCA: false elevation of serum CA 15-3 level in pregnant and lactating women by Ma695-Ma552-based assay.
Liang G; Fang X; Lin X; Feng X; Lu H; Wan Y; Gu Z
Breast Cancer Res Treat; 2018 Jun; 169(2):341-347. PubMed ID: 29396666
[TBL] [Abstract][Full Text] [Related]
15. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
Wang XF; Wu YH; Wang MS; Wang YS
Asian Pac J Cancer Prev; 2014; 15(1):363-8. PubMed ID: 24528057
[TBL] [Abstract][Full Text] [Related]
16. Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge.
Zhao S; Mei Y; Wang J; Zhang K; Ma R
PLoS One; 2016; 11(6):e0157639. PubMed ID: 27327081
[TBL] [Abstract][Full Text] [Related]
17. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer.
Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K
J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314
[TBL] [Abstract][Full Text] [Related]
18. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
19. A new tumor biomarker, serum protein peak at 3,144 m/z, in patients with node-positive breast cancer.
Chen Z; Xu S; Su D; Liu W; Yang H; Xie S; Meng X; Lei L; Wang X
Clin Transl Oncol; 2015 Jun; 17(6):486-94. PubMed ID: 25511546
[TBL] [Abstract][Full Text] [Related]
20. [The test system to identify mucin MUC1 in human blood serum using the technique of immune-enzyme analysis based on monoclonal antibody ICO25].
Karmakova TA; Vorontsova MS; Skripnik VV; Bezborodova OA; Iakubovskaia RI
Klin Lab Diagn; 2012 Feb; (2):53-6. PubMed ID: 22624465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
